AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept study (POC) with its cannabidiol (CBD) and Gabapentin chewing gum product to treat restless leg syndrome (RLS) in patients.

The PK and double blind, randomized, single-center phase 2 trial, which will be conducted in Israel by the CRO, will demonstrate the efficacy of AXIM’s chewing gum product composed of Gabapentin and CBD on around 30 study participants to treat RLS.

“We are excited to be able to contract with an Israeli CRO to conduct a pre- and a clinical proof-of-concept study for this unmet medical need condition. Israel is in the forefront of clinical cannabinoid research and we are thankful for having this opportunity. RLS is a prevalent condition affecting between 3.9-14.3% of the US population. The available treatments are not very effective and often cause severe side effects,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “We hope that our proprietary treatment modality utilizing cannabinoids and gabapentin in functional chewing gum will prove to be effective in alleviating the symptoms of RLS.”

Restless leg syndrome (RLS), also known as Willis-Ekbom Disorder (WED), is a condition associated with nocturnal sensorimotor symptoms, or nocturnal spasms of the muscles of the lower extremities, that can result in significant sleep disruption and severe pain. RLS is a prevalent condition, affecting an estimated 3.9-14.3 % of the US population. RLS can negatively affect a patient’s quality of life (QoL) across several domains, such as daytime sleepiness, decreased general health, decreased immune function, stress and mood

About AXIM [(R)] 

AXIM(R) Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew(R), a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM [(R)] Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media [email protected] P. +1888 829-0070

Investor Relations Contact: Shiwei Yin, Grayling [email protected] P. +1646 284-9474 Lucia Domville, Grayling [email protected] P. +1646 284-9416

Corporate Contact Info

North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246

European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227